CARsgen Therapeutics (HKG:2171) reported 75.5 million yuan in attributable loss for the half ended June 30, narrowing from a loss of 351.6 million yuan in the year-ago period, according to a Hong Kong bourse filing on Thursday.
Loss per share was 0.14 yuan, compared with 0.63 yuan in the prior year.
Revenue for the period jumped to 51 million yuan from 6.3 million yuan, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.